Bomyntra (denosumab)
pCPA File Number:
23493
Negotiation Status:
Active Negotiation
Indication(s):
• reducing the risk of developing skeletal-related events in patients with multiple myeloma and in patients with bone metastases from breast cancer, prostate cancer, non-small cell lung cancer, and other solid tumors;
• treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severemorbidity; and
• treatment of hypercalcemia of malignancy that is refractory to intravenous bisphosphonate
• treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severemorbidity; and
• treatment of hypercalcemia of malignancy that is refractory to intravenous bisphosphonate
Sponsor/Manufacturer:
Fresenius Kabi Canada Ltd.
CDA-AMC Project Number:
Not Applicable
pCPA Engagement Letter Issued:
Negotiation Process Concluded:
Not Applicable